跳转至内容
Merck
CN

I6034

α- L -艾杜糖醛酸酶 人

recombinant, expressed in mouse NSO cells

别名:

IDUA

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

UNSPSC Code:
12352204
NACRES:
NA.54
Specific activity:
≥7,500 units/μg protein
Recombinant:
expressed in mouse NSO cells
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


recombinant

expressed in mouse NSO cells

Quality Level

form

solution

specific activity

≥7,500 units/μg protein

mol wt

83 kDa

impurities

≤1.0 EU/μg Endotoxin

shipped in

wet ice

storage temp.

−20°C

General description

α-L-艾杜糖苷酸酶 (IDUA) 定位于人染色体4p16.3。成熟的IDUA蛋白被糖基化,并包含三糖磷酸异构酶(TIM)桶状结构域、β夹心式螺旋-环-螺旋区域和免疫球蛋白样结构域。α-L-艾杜糖苷酸酶被归类为糖苷水解酶(GH)家族39。
在 SDS-PAGE 还原条件下,表达为 C-末端组氨酸标记蛋白(残基 1-653),其含钙核分子量为 71 kDa,在约 83 kDa 处迁移。

Application

α-L-艾杜糖醛酸酶可用于新生儿 a-L-艾杜糖醛酸酶缺乏症的白细胞测定。

Biochem/physiol Actions

α-L-艾杜糖苷酸酶突变与粘多糖贮积病I型(MPS I)有关。该酶的缺陷导致皮肤素和硫酸乙酰肝素的积累。MPS I的病理生理学伴随着颅骨变形、智力低下和疝气。
催化硫酸皮肤素中未硫酸化的 L -艾杜糖苷键的水解
在溶酶体降解过程中,α-L-艾杜糖苷酸酶(Iduronidase )起着至关重要的作用。它水解糖胺聚糖(GAG)(包括硫酸皮肤素和硫酸乙酰肝素) 中非还原末端的α L-艾杜糖醛酸残基。

Physical form

40 mM 醋酸钠、400 mM NaCl 和 20% (v/v) 甘油溶液 (pH 5.0)

Other Notes

一个单元将在-25°C pH 3.5 下每分钟从 4-甲基伞形酮-α-L-艾杜糖苷酸生成 1 皮摩尔的 4-甲基伞形酮。


存储类别

10 - Combustible liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

常规特殊物品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Mei Dai et al.
Proceedings of the National Academy of Sciences of the United States of America, 111(7), 2680-2685 (2014-02-20)
Use of megakaryocytes/platelets for transgene expression may take advantage of their rapid turnover and protective storage in platelets and reduce the risk of activating oncogenes in hematopoietic stem and progenitor cells (HSCs). Here, we show that human megakaryocytic cells could
Akemi Tanaka et al.
Molecular genetics and metabolism, 107(3), 513-520 (2012-10-02)
Hematopoietic stem cell transplantation (HSCT) has not been indicated for patients with mucopolysaccharidosis II (MPS II, Hunter syndrome), while it is indicated for mucopolysaccharidosis I (MPS I) patients <2 years of age and an intelligence quotient (IQ) of ≥ 70.
Kristin D'Aco et al.
European journal of pediatrics, 171(6), 911-919 (2012-01-12)
Our objective was to assess how the diagnosis and treatment of mucopolysaccharidosis I (MPS I) have changed over time. We used data from 891 patients in the MPS I Registry, an international observational database, to analyze ages at symptom onset



全球贸易项目编号

货号GTIN
I6034-10UG04061833857663